Diagnostic potential of circulating cell-free nuclear and mitochondrial DNA for several cancer types and nonmalignant diseases: A study on suspected cancer patients

被引:8
作者
Sundquist, Kristina [1 ]
Sundquist, Jan [1 ]
Hedelius, Anna [1 ]
Memon, Ashfaque A. [1 ]
机构
[1] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
关键词
biomarker; cancer; circulating DNA; diagnostic; mitochondrial DNA; nuclear DNA; ORIGIN; PLASMA; QUANTIFICATION;
D O I
10.1002/mc.23261
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Circulating cell-free nuclear DNA (nDNA) has been implicated in individual cancer types with a diagnostic value; however, the role of cell-free mitochondrial DNA (mtDNA) in cancers is controversial. We aimed to investigate and compare the diagnostic potential of both nDNA and mtDNA for multiple cancers and to investigate their ability to distinguish multiple cancers from healthy controls and from nonmalignant diseases. We also investigated the prognostic value of both nDNA and mtDNA. The absolute copy number of circulating DNAs in suspected cancer patients (n = 286) referred to a cancer diagnostic center and healthy controls (n = 109) was quantified by droplet digital polymerase chain reaction. Among the suspected cancer patients, 66 (23%) were diagnosed with various cancers, 193 (67%) with nonmalignant diseases, and 27 (10%) with no active disease. Levels of nDNA were significantly higher in cancers (copies/mu l; mean +/- SD, 21.0 +/- 14.2) as compared with nonmalignant diseases (15.2 +/- 10.0) and controls (9.3 +/- 4.1). In contrast, levels of mtDNA were significantly lower in cancers (copies/mu l; mean +/- SD, 68,557 +/- 66,663) and nonmalignant diseases (60,174 +/- 55,831) as compared with controls (98,714 +/- 77,789). Receiver operating curve analysis showed that nDNA not only could distinguish multiple cancers from controls (area under curve [AUC] = 0.78; 95% confidence interval [CI] = 0.70-0.86) but also from nonmalignant diseases (AUC = 0.68; 95% CI = 0.59-0.76). However, mtDNA could only differentiate cancers from controls (AUC = 0.65; 95% CI = 0.56-0.73). Higher levels of nDNA were also associated with increased mortality in the cancer patients (hazard ratio = 2.3; 95% CI = 1.1-4.7). Circulating cell-free nDNA, but not the mtDNA, could distinguish multiple cancers from nonmalignant diseases and was associated with poor survival of cancer patients.
引用
收藏
页码:1362 / 1370
页数:9
相关论文
共 24 条
[1]   Circulating mitochondria DNA, a non-invasive cancer diagnostic biomarker candidate [J].
Afrifa, Justice ;
Zhao, Tie ;
Yu, Jingcui .
MITOCHONDRION, 2019, 47 :238-243
[2]   Quantification of mitochondrial DNA copy number: Pre-analytical factors [J].
Andreu, Antonio L. ;
Martinez, Ramiro ;
Marti, Ramon ;
Garcia-Arumi, Elena .
MITOCHONDRION, 2009, 9 (04) :242-246
[3]  
[Anonymous], BLOOD DONATION SWEDE
[4]   Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies [J].
Bettegowda, Chetan ;
Sausen, Mark ;
Leary, Rebecca J. ;
Kinde, Isaac ;
Wang, Yuxuan ;
Agrawal, Nishant ;
Bartlett, Bjarne R. ;
Wang, Hao ;
Luber, Brandon ;
Alani, Rhoda M. ;
Antonarakis, Emmanuel S. ;
Azad, Nilofer S. ;
Bardelli, Alberto ;
Brem, Henry ;
Cameron, John L. ;
Lee, Clarence C. ;
Fecher, Leslie A. ;
Gallia, Gary L. ;
Gibbs, Peter ;
Le, Dung ;
Giuntoli, Robert L. ;
Goggins, Michael ;
Hogarty, Michael D. ;
Holdhoff, Matthias ;
Hong, Seung-Mo ;
Jiao, Yuchen ;
Juhl, Hartmut H. ;
Kim, Jenny J. ;
Siravegna, Giulia ;
Laheru, Daniel A. ;
Lauricella, Calogero ;
Lim, Michael ;
Lipson, Evan J. ;
Marie, Suely Kazue Nagahashi ;
Netto, George J. ;
Oliner, Kelly S. ;
Olivi, Alessandro ;
Olsson, Louise ;
Riggins, Gregory J. ;
Sartore-Bianchi, Andrea ;
Schmidt, Kerstin ;
Shih, Ie-Ming ;
Oba-Shinjo, Sueli Mieko ;
Siena, Salvatore ;
Theodorescu, Dan ;
Tie, Jeanne ;
Harkins, Timothy T. ;
Veronese, Silvio ;
Wang, Tian-Li ;
Weingart, Jon D. .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
[5]   A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR [J].
Cavallone, Luca ;
Aldamry, Mohammed ;
Lafleur, Josiane ;
Lan, Cathy ;
Ginestet, Pablo Gonzalez ;
Alirezaie, Najmeh ;
Ferrario, Cristiano ;
Aguilar-Mahecha, Adriana ;
Basik, Mark .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2019, 28 (05) :909-916
[6]   Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification [J].
Devonshire, Alison S. ;
Whale, Alexandra S. ;
Gutteridge, Alice ;
Jones, Gerwyn ;
Cowen, Simon ;
Foy, Carole A. ;
Huggett, Jim F. .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2014, 406 (26) :6499-6512
[7]   The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers [J].
Diaz, Luis A., Jr. ;
Williams, Richard T. ;
Wu, Jian ;
Kinde, Isaac ;
Hecht, J. Randolph ;
Berlin, Jordan ;
Allen, Benjamin ;
Bozic, Ivana ;
Reiter, Johannes G. ;
Nowak, Martin A. ;
Kinzler, Kenneth W. ;
Oliner, Kelly S. ;
Vogelstein, Bert .
NATURE, 2012, 486 (7404) :537-540
[8]   Detection and quantification of mutations in the plasma of patients with colorectal tumors [J].
Diehl, F ;
Li, M ;
Dressman, D ;
He, YP ;
Shen, D ;
Szabo, S ;
Diaz, LA ;
Goodman, SN ;
David, KA ;
Juhl, H ;
Kinzler, KW ;
Vogelstein, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) :16368-16373
[9]  
Jahr S, 2001, CANCER RES, V61, P1659
[10]   Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer [J].
Keseru, Judit Szilvia ;
Soltesz, Beata ;
Lukacs, Janos ;
Marton, Eva ;
Szilagyi-Boniz, Melinda ;
Penyige, Andras ;
Poka, Robert ;
Nagy, Balint .
JOURNAL OF BIOTECHNOLOGY, 2019, 298 :76-81